Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Minimally invasive suturing for vascular bore closure and heart defect repair

Projektbeschreibung

Sicherere großlumige Gefäßverschlussvorrichtung

Bedeutende Fortschritte in der Medizintechnik haben die Entwicklung von Transkatheterverfahren ermöglicht, die Operationen am offenen Herzen ersetzen sollen. Diese Verfahren führen zu besseren klinischen Ergebnissen, kürzeren Krankenhausaufenthalten und schnelleren Erholungszeiten, erfordern jedoch große Zugangsstellen in den Gefäßen. Der Verschluss dieser großen Zugangsstellen ist mit einer hohen Komplikationsrate verbunden. Im Rahmen des EIC-finanzierten Projekts NVCD wird eine projekteigene Mikronahttechnik entwickelt, um einen effizienteren und sichereren großlumigen Gefäßverschluss zu erzielen. Nach der Prototypentwicklung und präklinischen Validierung werden im Zuge des Projekts klinische Studien durchgeführt, um die CE-Zertifizierung für die kommerzielle Nutzung der Nahtvorrichtung zu erhalten.

Ziel

Cardiovascular diseases (CVDs) remain a major health problem worldwide and a leading cause of mortality, with over annual 18 million deaths. In Europe, CVDs are associated with 4 million deaths and costs of around 210 billion per year.
Many surgeries to treat cardiac conditions are shifting to be minimally invasive and this is a trend expected to continue growing due to its multiple advantages over open interventions. However, as newly developed devices for transcatheter procedures become bigger they also require larger vascular access sites. A couple of devices are used in vascular large-bore closure (e.g. ProGlide from Abbott). However, they are associated with still high vascular and bleeding complications (up to 20%, depending on the operators skills). Such complications are linked to longer hospitalizations, unnecessary suffering, and greater healthcare costs (20k per patient), as well as higher morbidity and mortality.
To solve this persistent unmet need in the field of cardiovascular surgery, Novelrad has specifically developed the NVCD closure device. It integrates a proprietary and revolutionary micro-suturing technology that mimics the standard surgical technique, effectively delivering a multipoint continuous suture in a minimally invasive manner. The NVCD is easy to use and enables a safer closure of large bores, potentially reducing complication rates to 3%, saving up to 15 min in the procedure, and bringing important cost savings related to same-day discharge and complications management. Importantly, with a single NVCD device large and extra-large bore closure of veins and arteries is possible (up to 30Fr).
After obtaining a fully functional prototype of the NVCD and advancing in pre-clinical tests, we now aim to perform a first-in-human (FIH) study and complete the clinical trial required to obtain its CE certification as a Class III medical device. This will be crucial to prepare for industrialization and commercial deployment in Europe and globally.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIC-2023-ACCELERATOR-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

NOVELRAD LTD
Netto-EU-Beitrag
€ 2 499 999,00
Adresse
KIBBUTZ METZER
3882000 METZER
Israel
KMU
Ja
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 4 121 068,75